Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GDC-0068 plus mFOLFOX6 versus placebo plus mFOLFOX6 in advanced gastric or gastroesophageal junction adenocarcinoma
2012-002080-10Phase 2Unknown
- Sponsor
- Genentech
- Start
- Aug 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma comparing Ipatasertib plus mFOLFOX6 with Placebo plus mFOLFOX6 (2 arms). Primary endpoint: Progression-free survival. Status: unknown.
02
Drugs
ipatasertib
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2012-002080-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002080-10.